Skip to main content
×
Blacklisted Listed News Logo
Menu - Navigation
Menu - Navigation

Cited Sources

2nd Smartest Guy in the World
2nd Amendment Shirts
10th Amendment Center
Aaron Mate
Activist Post
AIER
Aletho News
Ammo.com
AmmoLand
Alliance for Natural Health, The
Alt-Market
American Free Press
Antiwar
Armstrong Economics
Art of Liberty
AUTOMATIC EARTH, The
Ben Bartee
Benny Wills
Big League Politics
Black Vault, The
BOMBTHROWER
Brandon Turbeville
Breaking Defense
Breitbart
Brownstone Institute
Burning Platform, The
Business Insider
Business Week
Caitlin Johnstone
Campus Reform
CAPITALIST EXPLOITS
Charles Hugh Smith
Children's Health Defense
CHRISTOPHE BARRAUD
Chris Wick
CIAgate
Citizen Free Press
Citizens for Legit Gov.
CNN Money
Collective Evolution
Common Dreams
Conscious Resistance Network
Corbett Report
Counter Signal, The
Cryptogon
Cryptome
Daily Bell, The
Daily Reckoning, The
Daily Veracity
DANERIC'S ELLIOTT WAVES
Dark Journalist
David Haggith
Defense Industry Daily
Defense Link
Defense One
Dennis Broe
DOLLAR COLLAPSE
DR. HOUSING BUBBLE
Dr. Robert Malone
Drs. Wolfson
Drudge Report
Economic Collapse, The
ECONOMIC POPULIST, The
Electronic Frontier Foundation
Ellen Brown
Emerald Robinson
Expose, The
F. William Engdahl
FAIR
Farm Wars
Faux Capitalist
FINANCIAL REVOLUTIONIST
Forbes
Foreign Policy Journal
FOREXLIVE
Foundation For Economic Freedom
Free Thought Project, The
From Behind Enemy Lines
From The Trenches
FUNDIST
Future of Freedom Foundation
Futurism
GAINS PAINS & CAPITAL
GEFIRA
Geopolitical Monitor
Glenn Greenwald
Global Research
Global Security
GM RESEARCH
GOLD CORE
Grayzone, The
Great Game India
Guadalajara Geopolitics
Helen Caldicott
Homeland Sec. Newswire
Human Events
I bank Coin
IEEE
IMPLODE-EXPLODE
Information Clearing House
Information Liberation
Infowars
Insider Paper
Intel News
Intercept, The
Jane's
Jay's Analysis
Jeff Rense
John Adams
John Pilger
John W. Whitehead
Jonathan Cook
Jon Rappoport
Jordan Schachtel
Just The News
Kevin Barret
Kitco
Last American Vagabond, The
Lew Rockwell
Le·gal In·sur·rec·tion
Libertarian Institute, The
Libertas Bella
LIBERTY BLITZKRIEG
LIBERTY Forcast
Liberty Unyielding
Market Oracle
Market Watch
Maryanne Demasi
Matt Taibbi
Medical Express
Media Monarchy
Mercola
Michael Snyder
Michael Tracey
Middle East Monitor
Mike "Mish" Shedlock
Military Info Tech
Mind Unleashed, The
Mint Press
MISES INSTITUTE
Mises Wire
MISH TALK
Money News
Moon of Alabama
Motherboard
My Budget 360
Naked Capitalism
Natural News
New American, The
New Eastern Outlook
News Deck
New World Next Week
Nicholas Creed
OF TWO MINDS
Off-Guardian
Oil Price
OPEN THE BOOKS
Organic Prepper, The
PANDEMIC: WAR ROOM
PETER SCHIFF
Phantom Report
Pierre Kory
Political Vigilante
Public Intelligence
Rair
Reclaim The Net
Revolver
Richard Dolan
Right Turn News
Rokfin
RTT News
Rutherford Institute
SAFEHAVEN
SAKER, The
Shadow Stats
SGT Report
Shadowproof
Slay News
Slog, The
SLOPE OF HOPE
Solari
South Front
Sovereign Man
Spacewar
spiked
SPOTGAMMA
Steve Kirsch
Steve Quayle
Strange Sounds
Strike The Root
Summit News
Survival Podcast, The
Tech Dirt
Technocracy News
Techno Fog
Terry Wahls, M.D.
TF METALS REPORT
THEMIS TRADING
Tom Renz
True Activist
unlimited hangout
UNREDACTED
Unreported Truths
Unz Review, The
VALUE WALK
Vigilant Citizen
Voltaire
Waking Times
Wall Street Journal
Wallstreet on Parade
Wayne Madsen
What Really Happened
Whitney Webb
winter oak
Wolf Street
Zero Hedge

Moderna Applies For Emergency COVID Vaccine Approval In US & Europe

Published: November 30, 2020 | Print Friendly and PDF
  Gab
Share

Source: ZeroHedge

In a repeat of the last three Mondays, positive COVID vaccine news has delivered a jolt to stocks as Moderna has confirmed that it has applied for emergency approval. The company will ask regulators in the US (the FDA) and Europe, as the vaccine is set to become the second COVID-19 vaccine to go into service.

According to the company, in the 30,000-person trial, 196 subjects developed COVID-19 with symptoms after receiving either the vaccine or a placebo. Of those, 185 had taken a placebo, while only 11 had gotten the vaccine, indicating it protects against the disease.

If the FDA clears the shot, distribution could start within weeks. "I think this vaccine is going to be really a game changer for this pandemic," said Moderna Chief Executive Stéphane Bancel said in an interview with WSJ. "We think it can really prevent severe disease."

Minutes after the news broke, Bancel appeared on CNBC Monday morning to answer some questions. During the interview, he said the vaccine is "a premium product" intended for health-care workers, the elderly and others with "high risk". The company is in discussions with Covax, the international program to deliver vaccines to the developing world, to supply some of its vaccines to the program.

Moderna shares surged on the results, climbing more than 10% to their highest levels yet.

Bancel said that trials for minors - broken into two groups, teenagers and younger children - could start later this year and early next year.

Moderna two weeks ago reported preliminary results from the first 95 Covid-19 cases to emerge in the trial, indicating the shot was 94.5% effective and looking safe.

Since then, another 101 volunteers developed symptomatic disease, enough to finish the analysis and potentially satisfy regulators.

In the final analysis, the company said there were 30 severe cases among the 196 total cases of Covid-19, and that all of them were among people who had gotten the placebo.

The most common side effects, the company said, included pain around the injection site, fatigue and headache. Moderna said the reactions increase in frequency and severity after the second dose of the vaccine.

The company now has two months of safety data following the second dose for at least half of the study subjects—a threshold the FDA is requiring before authorizing any Covid-19 vaccine.

The 10-year old biotech company is based in Cambridge, Mass. Moderna expects to have 20 million doses by the end of the year, enough for about 10 million people. Pfizer also expects to have a limited supply of its vaccine this year.

TOP TRENDING ARTICLES


PLEASE DISABLE AD BLOCKER TO VIEW DISQUS COMMENTS

Ad Blocking software disables some of the functionality of our website, including our comments section for some browsers.


Trending Now



BlackListed News 2006-2023
Privacy Policy
Terms of Service